IHAM
BBIO icon

Integral Health Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Integral Health Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-150,000
Closed -$2.5M – 77
2021
Q4 		$2.5M Buy
+150,000
New +$6.35M 0.69% 45

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Health Asset Management's BBIO Position: Q1 2026 in Review

Integral Health Asset Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 275,000 shares worth $20.4M. The stake represents 0.98% of the portfolio and ranks #24 among its holdings. This is a return to the name: Integral Health Asset Management previously reported a position in BBIO as recently as Q1 2025.

Integral Health Asset Management first reported a position in BBIO in Q3 2023 and has held it in 3 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Integral Health Asset Management held 275,000 shares of BridgeBio Pharma worth $20.4M as of Q1 2026.
  • BridgeBio Pharma was a new Integral Health Asset Management position in Q1 2026.
  • BridgeBio Pharma made up 0.98% of Integral Health Asset Management's portfolio in Q1 2026, its #24 holding.
  • Integral Health Asset Management first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 3 quarters since.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.